ARMATA PHARMACEUTICALS, INC. Stock Split Ratio
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Stock Split Ratio of 7.14% for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2022-03-17
- ARMATA PHARMACEUTICALS, INC. stockholders' equity note, stock split, conversion ratio for fiscal 2021 was 7.14%, a 0.00% change from fiscal 2020.
- ARMATA PHARMACEUTICALS, INC. stockholders' equity note, stock split, conversion ratio for fiscal 2020 was 7.14%, a 0.00% change from fiscal 2019.
- ARMATA PHARMACEUTICALS, INC. stockholders' equity note, stock split, conversion ratio for fiscal 2019 was 7.14%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|
| 2021-12-31 | 7.14% 10-K · filed 2022-03-17 | |||
| 2020-12-31 | 7.14% 10-K · filed 2021-03-18 | |||
| 2019-12-31 | 7.14% 10-K · filed 2020-03-19 | |||
| 2019-09-30 | 7.14% 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | 7.14% 10-Q · filed 2019-08-14 | |||
| 2019-05-09 | 7.14% 10-K · filed 2022-03-17 | |||
| 2017-04-24 | 1000.00% 10-K · filed 2019-03-25 | |||
| 2015-08-03 | 5000.00% 10-K · filed 2017-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |